Previous Close | 533.75 |
Open | 530.00 |
Bid | 535.06 x 1100 |
Ask | 536.00 x 1000 |
Day's Range | 527.56 - 535.50 |
52 Week Range | 383.12 - 553.29 |
Volume | |
Avg. Volume | 3,318,537 |
Market Cap | 501.978B |
Beta (5Y Monthly) | 0.76 |
PE Ratio (TTM) | 27.96 |
EPS (TTM) | 19.14 |
Earnings Date | Oct 12, 2022 - Oct 17, 2022 |
Forward Dividend & Yield | 6.60 (1.23%) |
Ex-Dividend Date | Jun 16, 2022 |
1y Target Est | 572.87 |
UnitedHealth (UNH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
UnitedHealth Group Inc, the top U.S. healthcare company by market capitalization, is struggling to sell Brazilian unit Amil due to antitrust issues and growing losses from individual health plans, according to four people with knowledge of the matter. After studying ways to divest Amil 10 years after acquiring it, UnitedHealth decided last month to suspend the sale process, the sources said, asking for anonymity because the discussions were private. UnitedHealth had agreed to pay acquirers for Amil's loss-making units and lose money on the sale of the whole company, but did not receive an attractive proposal, the sources added.